Contact this trialFirst, we need to learn more about you.
MDM2 Inhibitor
KRT-232 for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Nashville, Tennessee
This trial is testing a new oral medication called KRT-232 for patients with small cell lung cancer that has returned or resisted other treatments. The medication works by blocking a protein that helps cancer cells grow. The study will test different doses to find the most effective one. Niclosamide, originally a drug for treating parasitic infections, has shown potential in fighting small cell lung cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service